Bae, Ki Hyun http://orcid.org/0000-0001-8987-879X
Shunmuganathan, Bhuvaneshwari
Zhang, Li
Lim, Andrew
Gupta, Rashi http://orcid.org/0000-0001-8812-4144
Wang, Yanming
Chua, Boon Lin http://orcid.org/0009-0007-7661-6214
Wang, Yang
Gu, Yue
Qian, Xinlei
Tan, Isabelle Siang Ling
Purushotorman, Kiren http://orcid.org/0000-0002-6640-1144
MacAry, Paul A. http://orcid.org/0000-0002-1139-8996
White, Kevin P.
Yang, Yi Yan
Funding for this research was provided by:
Agency for Science, Technology and Research
National University of Singapore
Article History
Received: 12 October 2023
Accepted: 5 February 2024
First Online: 23 February 2024
Competing interests
: K.P.W. is an advisor and shareholder in Tempus Labs, Inc. and a director and shareholder in Provaxus, Inc. and its subsidiaries. A.L. is a shareholder in Provaxus, Inc. and its subsidiaries. P.A.M., B.S., R.G., and G.Y. are co-inventors of the surrogate viral neutralisation test used in this study, which has been commercialized as the ImTracker COVID-19 viral variant neutralisation test (GENY BIOLOGICS, ExternalRef removed).